Comparing the current results to its competitors, Black Diamond Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 11.17 %, recorded in the same quarter.
Black Diamond Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 38.65 %
Black Diamond Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a highly competitive industry characterized by rapid technological changes. It faces substantial competition from major pharmaceutical and biotechnology companies worldwide, many of which possess greater financial, technical, and human resources. Smaller and early-stage companies also represent significant competitors, particularly through collaborations with larger firms. Competitors may discover, develop, license, or commercialize products before or more successfully than the company. The company’s current and future product candidates, especially targeted therapies for genetically defined cancers, face competition. In particular, for the EGFR pathway, the company expects to compete against compounds including the combination of amivantamab, or Rybrevant, and other agents used in patients with EGFR acquired resistance.
September 22, 2024
Black Diamond Therapeutics Announces Initial Phase 2 BDTX-1535 Results in Recurrent EGFRm NSCLC Patients: A Promising Step Forward Black Diamond Therapeutics, a leading precision oncology medicine company, has announced an upcoming webcast presentation of initial Phase 2 data for BDTX-1535, a novel agent targeting EGFR mutations in patients with recurrent non-small cell lung cancer (NSCLC). The live presentation is scheduled for Monday, September 23, at 8:00 a.m. ET. Background and Study DesignNon-small cell lung cancer (NSCLC) remains one of the most challenging malignancies to treat, with EGFR mutations presenting in a significant subset of cases. Traditional treatments often face resistance, necessitating...
April 24, 2024
Black Diamond Therapeutics, Inc., a prominent clinical-stage oncology company committed to revolutionizing treatment paradigms, has recently revealed that it will play a key part at the forthcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Set to take place from May 31 to June 4 in Chicago, Illinois, the reputed event will witness two crucial poster presentations by Black Diamond, chiefly focusing on the application of BDTX-1535 in patients with recurrent glioblastoma (GBM).The Nasdaq-listed company is pioneering MasterKey therapies with the goal of targeting oncogenic mutations in cancer patients to help alleviate the disease burden and improve outcomes. As part of their relentless e...
Publicly Traded Peers of Black Diamond Therapeutics Inc
4d Molecular Therapeutics Inc Share Performance
+44.80%
This Quarter
4d Molecular Therapeutics Inc
Profile
4D Molecular Therapeutics Inc operates with a business model focused on developing innovative gene therapy products to address serious genetic diseases. The company utilizes its proprietary technology platform to design and optimize viral vectors for targeted gene delivery. With a strong commitment to research and development, 4D Molecular Therapeutics collaborates with partners in academia, industry, and patient organizations to advance transformative treatments for patients in need.
Kura Oncology Inc is a biotechnology company that focuses on the discovery and development of precision medicines for the treatment of cancer. Their business model revolves around leveraging their expertise in oncology to identify and design small molecule drug candidates that target specific genetic mutations or biomarkers. Through strategic partnerships and collaborations, Kura aims to advance their drug candidates through clinical studies and ultimately commercialize these precision medicines for patients in need.
LogicBio Therapeutics Inc is a biotechnology company that focuses on developing and commercializing gene editing technology to treat rare genetic diseases.
Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.
Mesoblast Ltd is a biotechnology company that operates on a business model focused on the development and commercialization of proprietary cell-based regenerative medicines. They aim to transform the treatment of various degenerative diseases by utilizing their patented technology and strategic partnerships with pharmaceutical companies.
Sources:
Black Diamond Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Black Diamond Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
